TERUMO CARDIOVASCULAR SYSTEMS CORPORATION VALVE, O.P.S BULK, N-S FOR TC; OVERPRESSURE SAFETY VALVE
|
Back to Search Results |
|
Model Number LN130BJ |
Device Problem
Leak/Splash (1354)
|
Patient Problem
No Patient Involvement (2645)
|
Event Date 09/27/2017 |
Event Type
malfunction
|
Manufacturer Narrative
|
Terumo has not received the device for evaluation; therefore, the investigation has yet to be completed.Terumo plans on submitting a follow-up report when the investigation is complete and when more information becomes available.(b)(4).Results: results pending completion of evaluation.Conclusions: conclusion not yet available-evaluation in progress.
|
|
Event Description
|
The user facility reported to terumo cardiovascular that prior to cardiopulmonary bypass, during prime, that there was a leak on the overpressure safety valve.No patient involvement as this occurred during prime.Product was changed out.Procedure was completed successfully.
|
|
Manufacturer Narrative
|
This follow-up report is submitted to fda in accord with applicable regulations.Upon further investigation of the reported event, the following information is new and/or changed: (b)(4).The returned sample was visually inspected.Slight deformation/damaged was found to one of the ports.The returned sample passed all leak tests and met all specifications therefore the complaint was not confirmed and the actual root cause can not be determined.It is possible that the unit had been over pressurized during use, causing the unit to leak.The other possibility would be the ops valve was placed in an aortic root vent line and the vent line was not properly clamped, therefore causing a positive pressure buildup in the vent line.The positive pressure relief valve then opened to release the pressure, and cause the ops valve to leak.This may have been the cause of the reported leak, if the valve was used in the aortic root vent line.However, a definitive root cause could not be determined.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|
|
Manufacturer Narrative
|
This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on october 20, 2017.A second follow-up will be submitted upon completion of the investigation and/or submission of new information.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|
|
Search Alerts/Recalls
|
|
|